Dezocine prevents sufentanil-induced cough during general anesthesia induction: a meta-analysis of randomised controlled trials.

ABSTRACT

BACKGROUND: Sufentanil is one of the opioids currently used to induce general anesthesia, and cough is one of the most common complications. Many drugs have been used to prevent sufentanil-induced cough (SIC), and dezocine is one of them. Dezocine is an analgesic, acting as partial antagonist of κ-receptors and agonist of µ-receptors. The purpose of our meta-analysis is to evaluate the efficacy of dezocine on SIC. METHODS: We searched multiple databases including PubMed, Embase, ScienceDirect, the Cochrane Library, and China National Knowledge Infrastructure databases (CNKI) to identify studies that met the inclusion criteria. This meta-analysis focused on the incidence and severity of SIC after dezocine intervention, as well as adverse effects. This meta-analysis was registered on PROSPERO with reference number ID CRD 42020144943. RESULTS: Five randomised controlled trials (RCTs) were identified, including 890 patients. Each study was a comparison of dezocine with an equal volume of 0.9% saline. When the injection dose of dezocine was 0.1 mg/kg, the incidence (pooled risk ratio (RR) = 0.03, [95% CI 0.02 to 0.07], P < 0.00001, I2 = 0%) and severity (mild RR = 0.07, [95% CI 0.03 to 0.18], P < 0.00001, I2 = 0%; moderate RR = 0.05, [95% CI 0.02 to 0.16], P < 0.00001, I2 = 0%; severe RR = 0.04, [95% CI 0.01 to 0.16], P < 0.00001, I2 = 0%) of SIC were significantly decreased. There were no statistically significant differences in vital signs between the two groups based on the results of the pooled analysis. CONCLUSION: This meta-analysis showed that dezocine significantly reduced the incidence and severity of SIC in the induction of general anesthesia, but had no significant effect on vital signs. More high-quality RCTs are needed to complement existing conclusions.